Peer-Reviewed Publication
Clin Infect Dis2023;77(11):1521-1530.November 30, 2023Randomized Controlled Trial
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
Yanfen Guan1, Amy Puenpatom1, Matthew G Johnson1, Ying Zhang1, Yujie Zhao1, Joseph Surber2, Aaron Weinberg3, Carlos Brotons4, Roman Kozlov5, Rudy Lopez6, Kathleen Coetzee7, Joel Santiaguel8, Jiejun Du1, Angela Williams-Diaz1, Michelle Brown1, Amanda Paschke1, Carisa De Anda1, Josephine M Norquist1
1Merck & Co, Inc, Rahway, New Jersey, USA.
2Centricity Research, Columbus, Georgia, USA.
3Carbon Health Technologies, Inc, North Hollywood, California, USA.
4EAP Sardenya, Biomedical Research Institute Sant Pau, Barcelona, Spain.
5Smolensk State Medical University, Smolensk, Russia.
6Clínica Médica Especialista en Pediatría e Infectología Pediátrica, Guatemala City, Guatemala.
7Paarl Research Centre, Paarl, South Africa.
8Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Abstract
BACKGROUND: Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants' self-reported symptoms in the MOVe-OUT trial, which evaluated molnupiravir initiated within 5 days of symptom onset in nonhospitalized, unvaccinated adults with mild-to-moderate, labo…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans